ArticleChemMedChem2026
Furagin Derivatives-Nitrofuran-Based Hydrazones as Potential Dual Inhibitors of Thioredoxin Reductase and Carbonic Anhydrases.
Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dual-target carbonic anhydrase inhibitors in cancer therapy: progress, challenges, and opportunities.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Cancer remains one of the leading causes of mortality, accounting for millions of deaths worldwide each year and posing a persistent challenge to global health despite advances in diagnosis and treatment. Dual inhibition of thioredoxin reductase (TrxR) and cancer-associated carbonic anhydrase (CA) isoforms IX and XII represents a promising strategy for selective anticancer therapy by simultaneously disrupting cellular redox homeostasis and pH regulation. The antibacterial agent furagin has been previously explored as an inhibitor of cancer-associated carbonic anhydrases; however, its potential as a TrxR inhibitor has not yet been investigated. In this study, a series of furagin derivatives-nitrofuran-based hydrazones (7a-7s)-were designed and synthesized as potential dual TrxR/CA inhibitors. The derivatives were screened for CA inhibition using a stopped-flow CO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.